Research context (RUO): Immune-system peptides such as Thymosin Alpha-1, Thymalin, VIP, LL-37 and KPV are signalling molecules that modulate the immune response in preclinical and clinical research. All substances mentioned on this page are supplied exclusively for in vitro laboratory research and are not intended for human or animal use.
Immune system peptides: research into immune modulation
Immune-system peptides form one of the most researched families within peptide science, because they do not shut down the immune system but fine-tune it. Where a classic medicine often fully suppresses or forces the immune system, these peptides act like a kind of control dial: they push a too-slow defence up and temper a runaway inflammatory response. Researchers call this immunomodulation. In this overview we discuss five peptides that are central in laboratories — Thymosin Alpha-1, Thymalin, VIP, LL-37 and KPV — and for each molecule describe the mechanism of action as reported in studies.
What are immune system peptides?
A peptide is a short chain of amino acids — smaller than a protein, larger than a single amino acid. The body uses such chains as messengers between cells. Immune-system peptides are specifically the messengers that communicate with immune cells: T lymphocytes, dendritic cells, macrophages and natural killer cells. Some of these peptides come naturally from the thymus, a gland that trains T cells. Others originate from the gut, the skin or the nervous system. What connects them in research is that they can shift the balance between attack and rest in the immune system. That makes them interesting for two opposite questions: strengthening a weakened defence, and dampening an overactive inflammatory response.
Thymosin Alpha-1 — the thymus messenger
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue. It is by far the best-documented immune peptide. Reviews describe that Tα1 binds to Toll-like receptors (notably TLR2, TLR7 and TLR9) on immune cells, thereby activating signalling pathways such as NF-κB and MyD88. The consequence researchers report: dendritic cells mature faster, T cells differentiate towards cytotoxic CD8+ cells, and the Th1 response — with cytokines such as interferon-γ and interleukin-2 — is strengthened. The activity of natural killer cells against virus-infected cells also increases in models.
Clinically, Tα1 (under the name thymalfasin) has been studied in several countries for hepatitis B and C. In a 2003 study, Tα1 was combined with interferon in hepatitis C, where the viral response was higher than with interferon alone (41.0% versus 26.3%). During the COVID-19 period, Tα1 was investigated in severe infections and sepsis, with mixed but much-discussed results. Anyone wanting to dive deeper into this topic will find more in our pillar Thymosin Alpha-1 research.
Thymalin — thymus extract for immune correction
Thymalin is not a single peptide but a polypeptide fraction obtained from thymic tissue. Especially in Russian research it is described as an agent for immune correction: it is said to restore the maturation and balance of T lymphocytes in a disturbed or aged immune system. Researchers therefore place Thymalin not only in immunology but also in gerontology — the field of ageing. In long-running studies in older subjects, Thymalin was associated with changes in immune parameters and with interest in the broader theme of healthy ageing. Because the immune system weakens with age (immunosenescence), this research overlaps with the broader field of longevity peptides. The underlying data is older and methodologically more limited than that of Tα1, which makes Thymalin an intriguing but less firmly substantiated object of study.
VIP — the anti-inflammatory neuropeptide
VIP stands for Vasoactive Intestinal Peptide, a 28-amino-acid molecule originally discovered in the gut but also active in the nervous system. In immunological research VIP is primarily an inhibitor of inflammation. It works via two receptors, VPAC1 and VPAC2, which activate a cAMP-dependent signalling pathway. The net effect reported in studies: macrophages produce fewer pro-inflammatory substances such as TNF-α, IL-12 and nitric oxide, while the anti-inflammatory cytokine IL-10 increases. At the T-cell level VIP shifts the balance: it suppresses Th1 and Th17 responses and promotes the development of regulatory T cells (Tregs), the “peacekeepers” of the immune system.
Because of this profile, VIP is studied in animal models of autoimmune and inflammatory diseases. Researchers reported protective effects in models of rheumatoid arthritis, colitis (intestinal inflammation) and septic shock. The idea is always the same: bringing an overactive immune system back to a more tolerant state without fully switching off the defences.
LL-37 — the antimicrobial peptide with a dual role
LL-37 is the only human cathelicidine and is formed from the precursor protein hCAP18. It owes its name to the two leucines (LL) at the start of the 37-amino-acid chain. In research LL-37 has two faces. First, it is directly antimicrobial: thanks to its positively charged, amphipathic α-helix structure it attaches to the negatively charged membranes of bacteria and disrupts them via a pore- or “carpet” mechanism, leading to death of the pathogen cell. Second, it is immunomodulatory: LL-37 attracts immune cells to the site of infection (chemotaxis), adjusts cytokine production, neutralises bacterial LPS (endotoxin) and promotes wound healing. Because of that combination, LL-37 is studied in laboratories as a target against resistant bacteria and in tissue repair, with researchers working on analogues that are more stable and less toxic.
KPV — the smallest anti-inflammatory
With three amino acids (Lysine-Proline-Valine), KPV is the smallest peptide in this overview. It is the C-terminal fragment of α-MSH (alpha-melanocyte-stimulating hormone), but lacks the pigmentation effects of the full hormone — exactly what makes it interesting as a “clean” anti-inflammatory. The mechanism researchers describe is elegant: KPV moves into the cell nucleus and there competitively blocks the interaction between importin-α and the p65/RelA subunit of NF-κB. Because NF-κB cannot enter the nucleus, the genes for inflammatory mediators such as TNF-α, IL-1β and IL-6 are not switched on.
A second striking feature is uptake in the gut: KPV is actively transported via the PepT1 transporter, which is expressed more strongly precisely in inflamed intestinal tissue. In mouse models of colitis (DSS- and TNBS-induced), oral KPV reduced the severity of inflammation, whereas PepT1 knock-out mice showed no effect — a neat confirmation that the transporter is the key. All this evidence is preclinical; human clinical studies are so far lacking.
Immune-system peptides in laboratory research: handling & dissolving
Most immune peptides are supplied as freeze-dried (lyophilised) powder in a vial and must be reconstituted before use in the lab, usually with bacteriostatic or sterile water. Smaller peptides such as KPV generally dissolve readily, whereas longer chains like LL-37 are more sensitive to the choice of solvent and pH. For the correct procedure and the right choice of liquid we refer to our pillars reconstitute peptides and dissolve peptide: which liquid. After reconstitution these peptides should be stored refrigerated and in the dark to limit degradation.
Quality & purity
With immune peptides, purity is not a detail but a research requirement: contaminants such as residual endotoxin can completely distort the measurement in an immunological assay, because immune cells respond precisely to such substances. Every relevant batch at Peplife is therefore independently HPLC-tested by an external laboratory; the certificate of analysis (CoA) is publicly verifiable per batch. How rigorous that process is, we illustrate in why we rejected a batch.
Frequently asked questions about immune-system peptides
What exactly are immune system peptides?
They are short amino-acid chains that in research communicate with immune cells and can strengthen or dampen the immune response. Well-known examples are Thymosin Alpha-1, Thymalin, VIP, LL-37 and KPV. They are supplied exclusively for laboratory research.
What is the difference between Thymosin Alpha-1 and Thymalin?
Thymosin Alpha-1 is a single, chemically defined 28-amino-acid peptide with extensive clinical literature. Thymalin is a polypeptide fraction from thymic tissue — a mixture — that has mainly been studied in older immune-correction and gerontology research.
Why is VIP called an anti-inflammatory peptide?
Because in studies VIP suppresses the production of inflammatory mediators such as TNF-α while at the same time promoting regulatory T cells. In animal models of rheumatoid arthritis, colitis and sepsis it was associated with a dampened inflammatory response.
Is LL-37 an antibiotic?
No. LL-37 is an endogenous antimicrobial peptide with a dual role: it directly damages bacterial membranes and also modulates the immune response. Researchers study it, among other things, as a target for resistant bacteria, but it is not a registered medicine.
Why is KPV interesting despite its small format?
Precisely because of its format. As a tripeptide, KPV blocks NF-κB inside the cell and is actively taken up in inflamed intestinal tissue via the PepT1 transporter. In mouse models of colitis this reduced the inflammation, although there is as yet no human clinical evidence.
Can I buy immune-system peptides at Peplife for my own use?
No. All peptides are sold exclusively for in vitro laboratory research (Research Use Only) and are not intended for diagnostic or therapeutic use in humans or animals.
Read more & research at Peplife
- Research Thymosin Alpha-1 at Peplife
- Research Thymalin at Peplife
- VIP (Vasoactive Intestinal Peptide) research at Peplife
- Research LL-37 at Peplife
- Research KPV at Peplife
- View all immune peptides
- Thymosin Alpha-1 research — the in-depth analysis
- Longevity peptides: research into ageing
Sources: Thymosin α1 and Its Role in Viral Infectious Diseases (Molecules, 2023) · The Use of Thymalin for Immunocorrection (PMC, 2021) · A Clinical Approach for the Use of the VIP Axis (Int. J. Mol. Sci., 2020) · Cathelicidin Family: Focus on LL-37 (Int. J. Mol. Sci., 2025) · PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation (PMC)
Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.
All immune peptides at Peplife are HPLC-tested by an external laboratory, with a per-batch verifiable CoA and discreet EU shipping.